The clinical information you need, at your fingertips.

Medical News for You

Circulation

Older HF patients benefit from meds—but many still don’t get them

New AHA statement urges clinicians to optimize guideline-directed therapy in older adults while accounting for frailty, cognition, polypharmacy, and goals of care. . .

AAO

GLP-1s and sudden vision loss: New guidance urges caution, not alarm

Ophthalmology consensus statement says semaglutide may carry a small possible NAION risk, but causation is unproven and treatment decisions should be individualized. . .

Lancet Oncol

AI outperforms standard scan criteria in mesothelioma assessment

AI-based tumor volume tracking found progression earlier and better predicted survival than standard imaging criteria. . .

N Engl J Med

Cefazolin matches standard therapy—and may be safer—for MSSA bacteremia

In a randomized SNAP trial analysis, cefazolin matched antistaphylococcal penicillins on 90-day mortality and caused less acute kidney injury. . .

FDA

FDA OKs first generic single-dose flu treatment

New generic option may improve affordability for influenza treatment and post-exposure prevention. . .

Criminology

GLP-1 use tied to weaker impulsivity-violence link

The drugs didn't lower impulsivity itself; they appeared to blunt how strongly it translated into violent acts. . .

PNAS Nexus

Tirzepatide bests semaglutide on weight loss, tolerability

In a matched real-world cohort of more than 20,000 patients, tirzepatide produced greater average weight loss as well as fewer GI, headache, and fatigue events than semaglutide. . .

FDA

FDA approves Utebzi, first oral carbapenem for complicated UTI

New oral option may help selected adults with resistant infections avoid prolonged IV therapy. . .

The clinical information you need, at your fingertips.

EPOCRATES CME

Clinical FAQs